SciClone Pharmaceuticals

Shanghai, China Founded: 1989 • Age: 37 yrs Acquired By BOC Investment
Specialty biopharma company that develops and commercializes specialist-oriented drugs
Request Access

About SciClone Pharmaceuticals

SciClone Pharmaceuticals is a company based in Shanghai (China) founded in 1989 was acquired by BOC Investment in June 2017.. SciClone Pharmaceuticals has completed 1 acquisition, including NovaMed Pharmaceuticals.

  • Headquarter Shanghai, China
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Sciclone Pharmaceuticals Inc
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of SciClone Pharmaceuticals
Headcount 500-1000
Employee Profiles 15
Employee Profiles
People
Elisabetta Perazzi
Senior Manager Of Manufacturing Science & Technology
People
Peter Shao
Vice President, Head of Technical Operations
People
Jiting Yan
BD Director
People
Polly Wong
Accounting Manager

Unlock access to complete

Funding Insights of SciClone Pharmaceuticals

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in SciClone Pharmaceuticals

SciClone Pharmaceuticals has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Ascendent Capital Partners, GL Capital and BOC Investment. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Private equity investments in China are managed by BOC Investment.
Founded Year Domain Location
Private equity and private debt firm focused on multiple sectors
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by SciClone Pharmaceuticals

SciClone Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include NovaMed Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Therapeutics for oncology, cardiovascular, and CNS disorders are developed.
2005
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - SciClone Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sciclone Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SciClone Pharmaceuticals

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Sciclone Pharmaceuticals

Frequently Asked Questions about SciClone Pharmaceuticals

When was SciClone Pharmaceuticals founded?

SciClone Pharmaceuticals was founded in 1989.

Where is SciClone Pharmaceuticals located?

SciClone Pharmaceuticals is headquartered in Shanghai, China.

What is the annual revenue of SciClone Pharmaceuticals?

Annual revenue of SciClone Pharmaceuticals is $160.1M as on Dec 31, 2016.

What does SciClone Pharmaceuticals do?

Sciclone is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. It has 7 marketed products in oncology and 1 product (Zadaxin) for HBV, HCV, immune system enhancement and sepsis. Product pipeline includes rapidfilm (CFDA reviewing CTA) and SGX942 (phase 2) in oncology; angiomax (CFDA review), neucardin (phase 3) and cleviprex (CTA application filed) in cardiovascular segment; and loramyc (In clinical testing) and vibativ (CTA application planning) in anti-infectives category.

How many acquisitions has SciClone Pharmaceuticals made?

SciClone Pharmaceuticals has made 1 acquisition, including NovaMed Pharmaceuticals.

Who are SciClone Pharmaceuticals's investors?

SciClone Pharmaceuticals has 4 investors. Key investors include Ascendent Capital Partners, GL Capital, BOC Investment, and CDH.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available